These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12050546)

  • 21. von Hippel-Lindau disease.
    Couch V; Lindor NM; Karnes PS; Michels VV
    Mayo Clin Proc; 2000 Mar; 75(3):265-72. PubMed ID: 10725953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of renal-cell cancer by transplantation of allogeneic stem cells.
    Burk RD
    N Engl J Med; 2001 Jan; 344(2):137; author reply 138. PubMed ID: 11188410
    [No Abstract]   [Full Text] [Related]  

  • 23. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
    Brauch H; Weirich G; Brieger J; Glavac D; Rödl H; Eichinger M; Feurer M; Weidt E; Puranakanitstha C; Neuhaus C; Pomer S; Brenner W; Schirmacher P; Störkel S; Rotter M; Masera A; Gugeler N; Decker HJ
    Cancer Res; 2000 Apr; 60(7):1942-8. PubMed ID: 10766184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A unique case of renal carcinoma with Xp11.2 translocations/ TFE3 gene fusions in a 3-year-old child, with coexistent von Hippel-Lindau gene mutation.
    Parast MM; Eudy G; Gow KW; Amin M; Shehata B
    Pediatr Dev Pathol; 2004; 7(4):403-6. PubMed ID: 15383938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiological evaluation, management, and surveillance of renal masses in Von Hippel-Lindau disease.
    Meister M; Choyke P; Anderson C; Patel U
    Clin Radiol; 2009 Jun; 64(6):589-600. PubMed ID: 19414081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions.
    Esteban-Barragán MA; Avila P; Alvarez-Tejado M; Gutiérrez MD; García-Pardo A; Sánchez-Madrid F; Landázuri MO
    Cancer Res; 2002 May; 62(10):2929-36. PubMed ID: 12019174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
    Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
    Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [VHL gene and TSC 2 gene].
    Hino O
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1386-91. PubMed ID: 9309130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Focus on kidney cancer.
    Linehan WM; Zbar B
    Cancer Cell; 2004 Sep; 6(3):223-8. PubMed ID: 15380513
    [No Abstract]   [Full Text] [Related]  

  • 32. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
    George DJ; Kaelin WG
    N Engl J Med; 2003 Jul; 349(5):419-21. PubMed ID: 12890838
    [No Abstract]   [Full Text] [Related]  

  • 33. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
    Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
    Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal lymphangioma.
    Joost J; Schäfer R; Altwein JE
    J Urol; 1977 Jul; 118(1 Pt 1):22-4. PubMed ID: 875189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
    Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
    Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of VHL gene mutation in human cancer.
    Kim WY; Kaelin WG
    J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythrocytosis and the Chuvash von Hippel-Lindau mutation.
    Percy MJ; Beard ME; Carter C; Thein SL
    Br J Haematol; 2003 Oct; 123(2):371-2. PubMed ID: 14531927
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention.
    Kume H; Takahashi S; Teramoto S; Isurugi K
    BJU Int; 2001 Nov; 88(7):804. PubMed ID: 11890260
    [No Abstract]   [Full Text] [Related]  

  • 40. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
    Igarashi H; Esumi M; Ishida H; Okada K
    Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.